SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study

Hsiang Lin Chan; Wei Che Chiu; Vincent Chin Hung Chen; Kuo You Huang; Tsu Nai Wang; Yena Lee; Roger S. McIntyre; Tsai Ching Hsu; Charles Tzu Chi Lee; Bor Show Tzang

doi:10.1002/pon.4493

SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study

Hsiang Lin Chan, Wei Che Chiu, Vincent Chin Hung Chen, Kuo You Huang, Tsu Nai Wang, Yena Lee, Roger S. McIntyre, Tsai Ching Hsu, Charles Tzu Chi Lee, Bor Show Tzang^*

^*Corresponding author for this work

Department of Health Promotion and Health Education

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. Objective: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. Methods: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. Results: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend <.001). Conclusions: All kinds of SSRIs were associated with decreased risk of HCC.

Original language	English
Pages (from-to)	187-192
Number of pages	6
Journal	Psycho-Oncology
Volume	27
Issue number	1
DOIs	https://doi.org/10.1002/pon.4493
Publication status	Published - 2018 Jan

Keywords

SSRIs
Taiwan national insurance
antidepressants
fluoxetine
hepatocellular carcinoma

ASJC Scopus subject areas

Experimental and Cognitive Psychology
Oncology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pon.4493

Cite this

@article{949c053ff2b14fa4b2506ec4635c78f6,

title = "SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study",

abstract = "Background: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. Objective: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. Methods: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. Results: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend <.001). Conclusions: All kinds of SSRIs were associated with decreased risk of HCC.",

keywords = "SSRIs, Taiwan national insurance, antidepressants, fluoxetine, hepatocellular carcinoma",

author = "Chan, {Hsiang Lin} and Chiu, {Wei Che} and Chen, {Vincent Chin Hung} and Huang, {Kuo You} and Wang, {Tsu Nai} and Yena Lee and McIntyre, {Roger S.} and Hsu, {Tsai Ching} and Lee, {Charles Tzu Chi} and Tzang, {Bor Show}",

note = "Publisher Copyright: Copyright {\textcopyright} 2017 John Wiley & Sons, Ltd.",

year = "2018",

month = jan,

doi = "10.1002/pon.4493",

language = "English",

volume = "27",

pages = "187--192",

journal = "Psycho-Oncology",

issn = "1057-9249",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - SSRIs associated with decreased risk of hepatocellular carcinoma

T2 - A population-based case-control study

AU - Chan, Hsiang Lin

AU - Chiu, Wei Che

AU - Chen, Vincent Chin Hung

AU - Huang, Kuo You

AU - Wang, Tsu Nai

AU - Lee, Yena

AU - McIntyre, Roger S.

AU - Hsu, Tsai Ching

AU - Lee, Charles Tzu Chi

AU - Tzang, Bor Show

PY - 2018/1

Y1 - 2018/1

N2 - Background: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. Objective: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. Methods: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. Results: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend <.001). Conclusions: All kinds of SSRIs were associated with decreased risk of HCC.

AB - Background: Hepatocellular carcinoma (HCC) is the second leading cancer-related cause of mortality worldwide. Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are commonly used worldwide. Available evidence investigating the association between SSRIs use and HCC risk is limited. Objective: The present study aimed to investigate if the effect of all kinds of SSRIs on HCC was the same or not using population-based study. Methods: The nationwide population-based study herein using Taiwan's National Health Insurance Research Database included a total of 59 859 cases with HCC and 285 124 matched controls. Conditional logistic regression analyses were adjusted for confounding variables. Results: All common kinds of SSRIs including fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine were associated with lower HCC risk, and the findings were dose-dependent (eg, fluoxetine: 1-28 DDD [defined daily dose]: adjusted odds ratio [aOR]: 0.81, 95% confidence interval [CI], 0.73-0.89; 29-365 DDD: aOR: 0.71, 95% CI, 0.64-0.79; and ≥366 DDD: aOR: 0.55, 95% CI, 0.45-0.67) (P for trend <.001). Conclusions: All kinds of SSRIs were associated with decreased risk of HCC.

KW - SSRIs

KW - Taiwan national insurance

KW - antidepressants

KW - fluoxetine

KW - hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85040809218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040809218&partnerID=8YFLogxK

U2 - 10.1002/pon.4493

DO - 10.1002/pon.4493

M3 - Article

C2 - 28666060

AN - SCOPUS:85040809218

SN - 1057-9249

VL - 27

SP - 187

EP - 192

JO - Psycho-Oncology

JF - Psycho-Oncology

IS - 1

ER -

SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this